Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 24;13:164. doi: 10.3389/fncel.2019.00164

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Lenoir, Varangot, Lebouvier, Galli, Hommet and Vivien.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Generation of the tPA-HaloTag®. (A) Scheme of the tPA-HaloTag® protein: tPA in blue (69 kDa), HaloTag® in orange (33 kDa) and the specific fluorescent exogenous ligand (HaloTag® TMR Ligand) in red. (B) Representative confocal images of HEK-293 cells transfected (+) or not (–) with pCMV_tPA-HaloTag®, incubated 48 h later (+) or not (–) in the presence of the HaloTag® TMR ligand, followed by immunocytochemistry (ICC) raised against tPA (blue). Scale Bar: 10 μm. (C) Fibrin–agar zymography showing the fibrinolytic activity of recombinant tPA (rtPA) as control and tPA-HaloTag® produced by HEK 293 transfected cells. (D) Immunoblots of recombinant tPA (rtPA) and proteins from HEK-293 cells culture transfected with pCMV_tPA-HaloTag® revealed with antibodies raised against either tPA or HaloTag®. Control tPA (rtPA).